Evidence map›Paper›PMID 28604584›Full record

ReviewInternational journal of molecular sciences2017

Lignin from Micro- to Nanosize: Production Methods.

Stefan Beisl, Angela Miltner, Anton Friedl

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Spheronized drug microcarrier system from canola straw lignin.Science and technology of advanced materials · 2023
    Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Multifunctional lignin-based nanocomposites and nanohybrids.Green chemistry : an international journal and green chemistry resource : GC · 2021
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Stefan BeislInstitute of Chemical, Environmental and Biological Engineering, TU Wien, 1060 Vienna, Austria. stefan.beisl@tuwien.ac.at.
Angela MiltnerInstitute of Chemical, Environmental and Biological Engineering, TU Wien, 1060 Vienna, Austria. angela.miltner@tuwien.ac.at.
Anton FriedlInstitute of Chemical, Environmental and Biological Engineering, TU Wien, 1060 Vienna, Austria. anton.friedl@tuwien.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lignin is the second most abundant biopolymer after cellulose. It has long been obtained as a by-product of cellulose production in pulp and paper production, but had rather low added-value applications. A changing paper market and the emergence of biorefinery projects should generate vast amounts of lignin with the potential of value addition. Nanomaterials offer unique properties and the preparation of lignin nanoparticles and other nanostructures has therefore gained interest as a promising technique to obtain value-added lignin products. Due to lignin's high structural and chemical heterogeneity, methods must be adapted to these different types. This review focuses on the ability of different formation methods to cope with the huge variety of lignin types and points out which particle characteristics can be achieved by which method. The current research's main focus is on pH and solvent-shifting methods where the latter can yield solid and hollow particles. Solvent shifting also showed the capability to cope with different lignin types and solvents and antisolvents, respectively. However, process conditions have to be adapted to every type of lignin and reduction of solvent demand or the integration in a biorefinery process chain must be focused.

Indexed as

LigninNanostructuresPaperLigninbiorefineryligninmicroparticlesnanoparticlesprecipitation

Identifiers

PMID28604584
PMCPMC5486067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.